Mdxk

South Korea Acquired By DKSH
Provider of life science research tools and services. This company supplies equipment and technologies for various applications, including multiomics, molecular biology, cellular biology, structural biology, and biobanking. They offer support services and provide access to cutting-edge technologies from leading manufacturers in the field. The company also shares research information and resources with its clients through publications and events. Their focus is on enabling researchers to conduct advanced life science investigations.

About Mdxk

Mdxk is a Healthcare company based in South Korea, and was acquired by DKSH in March 2025. Its focus areas include Traditional Medical Devices. Its legal entity in India is (μ£Ό)μ— λ””μ—‘μŠ€μΌ€μ΄ (U99999MH1977PLC010754).

Company details

Operations are conducted by Mdxk in South Korea within the life sciences sector. Equipment and technologies are supplied for applications including multiomics, molecular biology, cellular biology, structural biology, and biobanking. Support services are provided alongside access to technologies from various manufacturers. Research information and resources are shared with clients via publications and events. Researchers are enabled to perform investigations in these fields through these offerings.

Key Metrics

Investors in Mdxk

Mdxk has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include DKSH India.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Market expansion services are provided by DKSH across Asia.
1865dksh.comZurich, Switzerland
Premium access

Investor details for Mdxk

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Web traffic of Mdxk

The website of Mdxk (mdxk.co.kr) receives about 3K visits a month.

  • Monthly visits
    3K

    ▼ 1.8% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Mdxk

Premium access

Complete news archive for Mdxk

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mdxk

Mdxk is headquartered in South Korea.

Operations are conducted by Mdxk in South Korea within the life sciences sector. Equipment and technologies are supplied for applications including multiomics, molecular biology, cellular biology, structural biology, and biobanking. Support services are provided alongside access to technologies from various manufacturers. Research information and resources are shared with clients via publications and events. Researchers are enabled to perform investigations in these fields through these offerings.

Mdxk has 1 investor. Key investors include DKSH India.

Mdxk operates through ,.

Yes. Mdxk was acquired by DKSH in March 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available